About heron therapeutics inc. - HRTX
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.
HRTX At a Glance
Heron Therapeutics, Inc.
100 Regency Forest Drive
Cary, North Carolina 27518
| Phone | 1-858-251-4400 | Revenue | 144.29M | |
| Industry | Biotechnology | Net Income | -13,580,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 13.571% | |
| Fiscal Year-end | 12 / 2025 | Employees | 122 | |
| View SEC Filings |
HRTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.617 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -38.925 |
| Enterprise Value to Sales | 2.438 |
| Total Debt to Enterprise Value | 0.505 |
HRTX Efficiency
| Revenue/Employee | 1,182,663.934 |
| Income Per Employee | -111,311.475 |
| Receivables Turnover | 1.829 |
| Total Asset Turnover | 0.633 |
HRTX Liquidity
| Current Ratio | 2.285 |
| Quick Ratio | 1.704 |
| Cash Ratio | 0.648 |
HRTX Profitability
| Gross Margin | 73.214 |
| Operating Margin | -7.99 |
| Pretax Margin | -9.412 |
| Net Margin | -9.412 |
| Return on Assets | -5.961 |
| Return on Equity | N/A |
| Return on Total Capital | -9.423 |
| Return on Invested Capital | -9.575 |
HRTX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 123.351 |
| Total Debt to Total Assets | 76.245 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 121.243 |